Dermatological toxicity associated with the use of gilteritinib in relapsed acute myeloid leukemia with FLT3 mutation: a case report

被引：0
|
作者：
Roldan, Alicia Martin [1 ]
Alarcon-Payer, Carolina [1 ]
Suarez, Maria Del Mar Sanchez [1 ]
Morales, Alberto Jimenez [1 ]
机构：
[1] Hosp Univ Virgen Nieves, Hosp Pharm Dept, Granada 18014, Spain
来源：
ANTI-CANCER DRUGS | 2024年 / 35卷 / 09期
关键词：
FLT3; mutation; gilteritinib; granuloma annulare; neutrophilic dermatosis; relapsed/refractory AML; CHEMOTHERAPY; THERAPY;
D O I：
10.1097/CAD.0000000000001634
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
We present a case of a patient diagnosed with FLT3 mut+ acute myeloid leukemia with FLT3 and NMP1 mutations who did not respond to standard induction and consolidation treatment with chemotherapy. Due to the FLT3mut+ gene mutation and intermediate cytogenetic risk, treatment with gilteritinib is requested. After treatment she experienced a neutrophilic dermatosis and granuloma annulare that was resolved with gilteritinib dose reduction and specific treatment in coordination with the dermatology department.
引用
收藏
页码：872 / 874
页数：3
相关论文
共 50 条
  • [21] Erythroid differentiation of myeloblast induced by gilteritinib in relapsed FLT3-ITD-positive acute myeloid leukemia
    Yun, Hyun Don
    Nathan, Sunita
    Larson, Melissa
    Hussain, Mohammad J.
    Katz, Deborah A.
    Varma, Ankur
    Miller, Ira
    Ustun, Celalettin
    BLOOD ADVANCES, 2019, 3 (22) : 3709 - 3712
  • [22] FLT3 inhibitors in acute myeloid leukemia
    Pastore, Domenico
    DRUGS AND CELL THERAPIES IN HEMATOLOGY, 2016, 4 (01): : 14 - 21
  • [23] Clinical considerations for the use of FLT3 inhibitors in acute myeloid leukemia
    Weis, Taylor M.
    Marini, Bernard L.
    Bixby, Dale L.
    Perissinotti, Anthony J.
    CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2019, 141 : 125 - 138
  • [24] Safety of FLT3 inhibitors in patients with acute myeloid leukemia
    Cerchione, Claudio
    Peleteiro Raindo, Andres
    Mosquera Orgueira, Adrian
    Mosquera Torre, Alicia
    Bao Perez, Laura
    Marconi, Giovanni
    Isidori, Alessandro
    Perez Encinas, Manuel Mateo
    Martinelli, Giovanni
    EXPERT REVIEW OF HEMATOLOGY, 2021, 14 (09) : 851 - 865
  • [25] FLT3 inhibitors in acute myeloid leukemia: Current and future
    Thomas, Christan M.
    Campbell, Peter
    JOURNAL OF ONCOLOGY PHARMACY PRACTICE, 2019, 25 (01) : 163 - 171
  • [26] Emerging FLT3 inhibitors for the treatment of acute myeloid leukemia
    Solana-Altabella, Antonio
    Ballesta-Lopez, Octavio
    Megias-Vericat, Juan Eduardo
    Martinez-Cuadron, David
    Montesinos, Pau
    EXPERT OPINION ON EMERGING DRUGS, 2022, 27 (01) : 1 - 18
  • [27] Gilteritinib with or without venetoclax for relapsed/refractory FLT3-mutated acute myeloid leukaemia
    Kugler, Eitan
    Cohen, Inbar
    Amitai, Irina
    Ram, Ron
    Frisch, Avraham
    Nachmias, Boaz
    Canaani, Jonathan
    Moshe, Yakir
    Krayem, Baher
    Aumann, Shlomzion
    Henig, Israel
    Vainstein, Vladimir
    Shargian, Liat
    Ganzel, Chezi
    Yeshurun, Moshe
    Levi, Itay
    Raanani, Pia
    Akria, Luiza
    Ofran, Yishai
    Shimony, Shai
    Wolach, Ofir
    BRITISH JOURNAL OF HAEMATOLOGY, 2024, 205 (03) : 932 - 941
  • [28] FLT3 inhibitors for the treatment of acute myeloid leukemia
    Metzelder S.
    Röllig C.
    best practice onkologie, 2018, 13 (4) : 182 - 190
  • [29] Targeting FLT3 Mutations in Acute Myeloid Leukemia
    El Fakih, Riad
    Rasheed, Walid
    Hawsawi, Yousef
    Alsermani, Maamoun
    Hassanein, Mona
    CELLS, 2018, 7 (01)
  • [30] A review of FLT3 inhibitors in acute myeloid leukemia
    Zhao, Jennifer C.
    Agarwal, Sonal
    Ahmad, Hiba
    Amin, Kejal
    Bewersdorf, Jan Philipp
    Zeidan, Amer M.
    BLOOD REVIEWS, 2022, 52
12345